In what was a fait accompli after a failed outcomes study for Merck's (MRK -0.07%) cholesterol drug Tredaptive, the big pharma giant just announced it was suspending sales of the drug. Motley Fool health-care analyst David Williamson explains the embarrassing situation and what this means for investors.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.